UroPartners is committed to driving innovation through high‑quality clinical research. Here, patients can learn about ongoing and upcoming clinical trials designed to improve outcomes, expand treatment options, and advance the field of urology.
CORE-008
High risk non-muscle invasive bladder cancer with stage TA/CIS- BCG exposed patients to receive instillation of Cretostimogene Grenadenorepvec
CORE-008 2025 Annual Review Meeting Minutes (PDF)
CRETO- EAP
Patients with non-muscle invasive bladder cancer unresponsive to BCG to receive instillation of Cretostimogene Grenadenorepvec
CRETO-EAP 2025 Annual Review Meeting Minutes (PDF)
P23-1
Metastatic Castrate Resistant Prostate Cancer Patients Treatment With standard of care Provenge vs additional Provenge Booster dose
IsoPSA LV-5
Prostate Cancer-Blood/serum sample collection for patients on active surveillance or prostate cancer with a PSA 4.0 or below.
68GA-TLX 301
PSMA/PET scan combined with MRI scan in comparison to standard of care for the detection of prostate cancer.
Able32
Patients with Intermediate Risk non-muscle invasive bladder cancer receiving instillation of Nadofaragene Firadenovec vs. Observation
Immunity Bio- EAP
Bladder Cancer-An expanded access program allowing patients to receive BCG per standard of care guidelines.
EvoPar 01
Prostate Cancer- AZD5305 in Combination with Physician's Choice New Hormonal Agents in Participants with Metastatic Castration-Sensitive Prostate Cancer with and without HRRm (D9723C00001 - EvoPAR-Prostate 01)
PIVOT-006
Bladder Cancer- Study of Cretostimogene grenadenorepvec after TURBT vs TURBT for Intermediate-Risk NMIBC
OPTYX -058
Patients being treated with ORGOVYX for real world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer.
Confidence
Confirm mdx® for Prostate Cancer Decision on patients
Quilt 2.005
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer